Skip to main content

Table 4 Reported outcomes of recent cervical stereotactic ablative body radiotherapy boost studies

From: Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible

Authors

Study type

Number of patients

Median follow-up (months)

Pelvic RT total dose (Gy)

Pelvic RT dose per fractionation (Gy)

Boost total dose (Gy)

Boost dose per fractionation (Gy)

Local control

Overall survival

Progression-free survival

Late toxicity

(Grade 3 or worse)

Haas et al. [12]

Retrospective

6

14

50.4–61.2

1.8

19.5–20

4–6.5

100% (Overall)

100% (Overall)

100% (Overall)

0% (Overall)

Marnitz et al. [13]

Retrospective

11

6

50.4

1.8

30

6

100% (Overall)

100% (Overall)

100% (Overall)

0% (Overall)

Hsieh et al. [14]

Retrospective

9

NR

50–50.4

1.8–2

16–27

2–4.5

77.8% (3-year, LRC)

46.9% (3-year)

25.9%

(3-year)

0% (Overall)

Ito et al. [15]

Prospective phase I

6

17

45

1.8

21–22.5

7–7.5

100% (Overall)

100% (Overall)

83.3% (Overall)

0% (Overall)

Albuquerque et al. [16]

Prospective phase II

15

19

45

1.8

28

7

70.1% (2-year)

53.3% (2-year)

46.7%

(2-year)

26.7%

(2-year)

Dalwadi et al. [17]

Retrospective

25

25

45–50.4

1.8

12–30

4–7

95.5% (2-year, LRC)

95.5% (2-year)

NR

4.0% (Overall)

Current study

Retrospective

25

34.2

44–50.4

1.8–2

20–33

4–5.5

80.9% (3-year)

77.1% (3-year)

58.5%

(3-year)

20.0% (Overall)

  1. RT, radiotherapy; NR, not reported; LRC, locoregional control